Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Pogled internista onkologa na sistemsko zdravljenje raka požiralnika
Avtorji:ID Reberšek, Martina (Avtor)
ID Mesti, Tanja (Avtor)
ID Boc, Marko (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (377,91 KB)
MD5: D26475C23486C6121931D1D64470AC28
PID: 20.500.12556/dirros/541c461b-f955-47b6-b7ae-804060bc7e04
 
Jezik:Slovenski jezik
Tipologija:1.08 - Objavljeni znanstveni prispevek na konferenci
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Ključne besede:onkologija, rak požiralnika, sistemsko zdravljenje, rak prebavil
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2014
Št. strani:str. 34-38, 74
Številčenje:Letn. 18, št. 1
PID:20.500.12556/DiRROS-9019 Novo okno
UDK:616.3-006
ISSN pri članku:1408-1741
URN:URN:NBN:SI:doc-H68I2RZN
COBISS.SI-ID:1808507 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:31.08.2018
Število ogledov:3511
Število prenosov:928
Metapodatki:XML DC-XML DC-RDF
:
REBERŠEK, Martina, MESTI, Tanja in BOC, Marko, 2014, Pogled internista onkologa na sistemsko zdravljenje raka požiralnika. V : Šola: tumorji prebavil II, Ljubljana, 15. 11. 2013 [na spletu]. Objavljeni znanstveni prispevek na konferenci. 2014. p. 34–38, 74. [Dostopano 29 april 2025]. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=9019
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Šola: tumorji prebavil II, Ljubljana, 15. 11. 2013
Založnik:Onkološki inštitut
COBISS.SI-ID:1807227 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:31.08.2018

Sekundarni jezik

Jezik:Angleški jezik
Naslov:[Treatment of oesophageal cancer from the medical oncologists' point of view]
Povzetek:The incidence of carcinoma of the oesophagus in Slovenia is small and has not changed in years. The prognosis of patients with metastatic carcinoma of the oesophagus is poor, with less than 10% 5-year survival. In the early stages of the disease, we recommend surgical treatment in combination with neoadjuvant chemoradiation for squamous cell carcinoma or perioperative systemic chemotherapy for adenocarcinoma of the gastroesophageal junction. In locoregionally advanced carcinoma, we recommend neoadjuvant chemoradiation. In the case of cervical carcinoma of the oesophagus or in high-risk patients not fit for surgery, we recommend definitive chemoradiation. The most optimal systemic therapy for metastatic disease is selected based on the general state of the patient, his concurrent diseases, the expected toxicity of systemic therapy, and HER2 status in patients with adenocarcinoma. For first-line treatment, we recommend doublet chemotherapy, mainly due to a better toxicity profile. In the case of HER2-positive adenocarcinoma, doublet may be combined with trastuzumab. In patients who are in good general condition, we can try with a combination of three cytostatics. For patients in poor general condition, only palliative supportive care is recommended, since the benefit of such treatment outweighs the potential treatment complications. We are eagerly awaiting the results of the ongoing clinical trials of new combinations of cytostatics and targeted drugs, hoping for more effective combinations of drugs that would enable us to treat patients with metastatic carcinoma of the oesophagus and gastroesophageal junction more effectively


Arhiv

niGradiv

Nazaj